Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B

Maylin, Sarah; Sire, Jean-Marie; Mbaye, P. S.; Simon, François; Sarr, A.; Evra, Marie-Louise; Fall, Fatou; Daveiga, Jean; Diallo, Aboubakry; Debonne, Jean-Marc; Chartier, Loïc; Vray, Muriel

doi:10.1186/s12879-015-0881-4

Cited by 18 publications

(23 citation statements)

References 23 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in concordance with a Turkish study, which demonstrated that mean qHBsAg level in HBeAg‐negative patients with a viral load >10 5 copies/mL was significantly higher than in those with negative DNA . In this study, HBsAg/DNA ratio was higher in patients with low HBV DNA than in those with higher HBV DNA, similar to a study of 87 Senegalese CHB patients (75% with genotype E) . This reflects a disconnection between HBsAg production and HBV DNA replication and may be linked with higher frequency of mutation in the precore region.…”

Section: Discussionsupporting

confidence: 57%

See 1 more Smart Citation

Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?

Chakrabarty

Bruce

Horner

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

SummaryThe utility of quantitative Hepatitis B surface antigen (qHBsAg) level as a marker of chronic hepatitis B (CHB)-related liver damage is not fully delineated, but is becoming increasingly relevant. Quantitative HBsAg levels are linked with progression of liver disease in HBeAg-negative genotype B and C patients, but it is not clear whether this is consistent across all HBV genotypes. In this single-centre, cross-sectional observational study, we evaluated whether qHBsAg levels can predict the severity of liver disease in genotype E patients. Demographic characteristics, viral, biochemical markers and qHBsAg levels were assessed at time of liver biopsy [all HBV DNA>2000 IU/mL and/or abnormal alanine transaminase (ALT)]. Patients were divided into three groups according to the severity of fibrosis on biopsy: mild (F0-1), moderate (F2-4), severe (F5-6) liver disease and into two groups according to the NI grading, low (NI 0-3) and high inflammation (NI ≥4). A total of 259 HBeAg-negative CHB treatment-naive genotype E patients were studied. The median age of this cohort was 38 years, and 61% were males. Advanced (severe) fibrosis patients had higher ALT, HBV DNA, and lower HBsAg level and qHBsAg/DNA ratio. Patients with NI ≥4 had higher ALT, HBV DNA, but lower qHBsAg/DNA ratio. There was no correlation between HBsAg and HBV DNA levels. Quantitative HBsAg levels were lower in more advanced liver fibrosis.There was no correlation between qHBsAg and HBV DNA levels. This may reflect discordance between viral replication and transcriptional activity or differential HBsAg expression in HBeAg-negative genotype E patients with advanced liver disease.

show abstract

Section: Discussionsupporting

confidence: 57%

“…We do not have a detailed mutational analysis of the precore region for our cohort, but reports from small studies suggest that mutation may affect HBsAg levels . The impact of changes in the precore region on HBV replication in genotype E patients was demonstrated in two genotype E exclusive studies and one mixed genotype study …”

Section: Discussionmentioning

confidence: 99%

Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?

Chakrabarty

Bruce

Horner

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…However, in developing countries endemic for HBV (18), robust, cheaper, and easy-to-perform markers are essential in the management and monitoring of HBV patients (19). Hepatitis B viral load measurement is rarely accessible and where available often done once, which may not reflect real viral activity (19). tectable HBV DNA levels is still missing (20).…”

Section: Discussionmentioning

confidence: 99%

Correlation of Quantitative Assay of HBsAg and Hepatitis B Virus DNA Levels Among Chronic HBV Patients Attending Pathologist Lancet Laboratory in Nairobi, Kenya

Mathai

Ngayo

Karanja

et al. 2017

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Hepatitis B Virus (HBV) viral load measurements is recommended for diagnosis and monitoring of patients on treatment for Chronic Hepatitis B (CHB). However, these diagnostic techniques are molecular-based and expensive and unavailable to majority of the Kenyan population. Quantitation of hepatitis B surface antigen (HBsAg) by automated chemiluminescent microparticle immunoassay has been proposed as a surrogate marker. Objectives: This study showed the correlation between HBsAg and HBV DNA levels among patients with CHB attending a referral Laboratory in Nairobi, Kenya. Methods: One hundred and seventy-three (173) patients were enrolled while excluding Hepatitis C Virus (HCV) and Hepatitis D Virus (HDV) positive patients. Results:The mean age of the study patients was 37.2 years, 112 (64.7%) were male, and 142 (82.1%) were hepatitis B e antigen (HBeAg) negative while 31/173 (17.9%) were HBeAg positive. The mean HBV DNA level was 2.89 log10 IU/mL and 41 (23.7%) had a baseline HBV DNA level of > 2000 IU/mL. By Mann-Whitney test, HBV DNA levels differed significantly between HBeAg positive and negative patients (P = 0.001), as did HBsAg titer (P = 0.032). Unfortunately, according to the Spearman test, there was a weak correlation between HBsAg and HBV DNA levels (P = 0.024 and r = 0.171). Conclusions: Patients with HBeAg negative test results had lower levels of HBsAg and lower levels of HBV DNA. Serum quantitation of HBsAg may not replace serum HBV DNA levels among patients with CHB in Nairobi Kenya.

show abstract

“…Genotype D is prevalent in Turkey, although we have not analyzed the HBV genotype of our case [19]. HBs Ag seroclearance is very rarely seen as an annual rate of 2.4-3.2% with Peg-IFN treatment, and only <1% with nucleoside/nucleotide analogues [20]. Therefore, we have not expected a HBs Ag seroclearance in our case.…”

Section: Discussionmentioning

confidence: 93%

Chronic Hepatitis B Reactivation Subsequent to Chronic Hepatitis C Treatment: A Case Report

Gedık¹,

Parcaoglu²

2017

J Hep

View full text Add to dashboard Cite

Patients, who are coinfected with hepatitis B and C, are at high risk for a progression to severe liver disease (cirrhosis, decompensated liver disease), hepatocellular carcinoma, and unresponsiveness to treatment. In this article, a case who developed a reactivation of chronic hepatitis B subsequent to Chronic Hepatitis C (CHC) treatment is presented. A 42-year-old woman with HBV and HCV was admitted to infectious diseases clinic with a major complaint of fatigue for three months. Laboratory tests revealed an elevated alanine transaminase of 182 IU/L (Normal range: 0-55 IU/L), elevated aspartate transaminase of 150 IU/L, serum HCV-RNA levels of 2080195 IU/mL (genotype 1b), and HBV-DNA of 1184 IU/mL. The results of other laboratory tests were within the normal range and remained to be normal during the follow-up. Pegylated interferon alpha-2a (180 mcg/week) and ribavirin (1200 mg/day) were administered for the treatment of CHC for 48 weeks. After one year of CHC treatment, our case was admitted with the elevation in liver enzymes and HBV-DNA of 878215 IU/mL. The histopathological examination of liver tissue revealed a mildly active histologic activity (6/18) and a mildly active histological activity (1/6) according to ISHAK scoring. Tenofovir disoproxil tablet (245 mg/day) was initiated for the chronic hepatitis B treatment. The patient is followed up at the ambulatory clinic of infectious diseases. As a result, patients coinfected with HBV and HCV should be followed up for the reactivation of HBV after CHC treatment with either pegylated interferon-based therapy or oral direct-acting antiviral agents in the medium-term, and the cirrhosis and hepatocellular carcinoma in the long-term.

show abstract

Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B

Cited by 18 publications

References 23 publications

Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?

Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?

Correlation of Quantitative Assay of HBsAg and Hepatitis B Virus DNA Levels Among Chronic HBV Patients Attending Pathologist Lancet Laboratory in Nairobi, Kenya

Chronic Hepatitis B Reactivation Subsequent to Chronic Hepatitis C Treatment: A Case Report

Contact Info

Product

Resources

About